No Result
View All Result
SUBSCRIBE | NO FEES, NO PAYWALLS
MANAGE MY SUBSCRIPTION
NEWSLETTER
Corporate Compliance Insights
  • Home
  • About
    • About CCI
    • CCI Magazine
    • Writing for CCI
    • Career Connection
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Library
    • Download Whitepapers & Reports
    • Download eBooks
    • New: Living Your Best Compliance Life by Mary Shirley
    • New: Ethics and Compliance for Humans by Adam Balfour
    • 2021: Raise Your Game, Not Your Voice by Lentini-Walker & Tschida
    • CCI Press & Compliance Bookshelf
  • Podcasts
    • Great Women in Compliance
    • Unless: The Podcast (Hemma Lomax)
  • Research
  • Webinars
  • Events
  • Subscribe
Jump to a Section
  • At the Office
    • Ethics
    • HR Compliance
    • Leadership & Career
    • Well-Being at Work
  • Compliance & Risk
    • Compliance
    • FCPA
    • Fraud
    • Risk
  • Finserv & Audit
    • Financial Services
    • Internal Audit
  • Governance
    • ESG
    • Getting Governance Right
  • Infosec
    • Cybersecurity
    • Data Privacy
  • Opinion
    • Adam Balfour
    • Jim DeLoach
    • Mary Shirley
    • Yan Tougas
No Result
View All Result
Corporate Compliance Insights
Home Governance

Amarin Pharma Decision Reiterates Importance of Disclosures in Off-Label Promotion

by Brian A. Dahl
August 21, 2015
in Governance
Amarin Pharma Decision Reiterates Importance of Disclosures in Off-Label Promotion

The FDA wants to ignore the Second Circuit’s opinion in United States v. Caronia.

As I am frequently wont to do with my two sons, I quote the Rolling Stones in response to the FDA’s desire to disregard Caronia – “You can’t always get what you want.”

The agency does not want to allow off-label promotion of drugs – even off-label promotion that is truthful and non-misleading and includes appropriate disclosures.  As previously discussed, the agency is not opposed to off-label communication, as long as that communication more or less fits within guidance it has provided to the pharmaceutical industry.  But despite Caronia, the FDA wants to continue prohibiting truthful and non-misleading off-label promotion rather than look at less restrictive methods to address its interest in protecting the public from the potential risks of having this information available in the marketplace.

District Judge Paul A. Englemayer of the Southern District of New York took the FDA to task for its disregard of Caronia.  In his opinion in Amarin Pharma, Inc. v. FDA, Judge Englemayer stated:

“The Second Circuit’s decision in Caronia reflected a careful Central Hudson analysis.  And the Circuit, in Caronia, identified alternative, and less speech-restrictive, means for the FDA to achieve its objectives. The FDA’s quarrel is, therefore, ultimately, with Caronia.  Notably, however, despite a vigorous dissent to the effect that the panel majority had ‘call[ed] into question the very foundations of our century-old system of drug regulation,’ the Government neither sought rehearing nor petitioned for certiorari in Caronia (citation omitted).”

Conventional wisdom is that the FDA did not appeal Caronia because the agency thought it could distinguish the case by limiting it to its facts.

Judge Englemayer would have none of that in deciding that FDA could not prosecute Amarin for misbranding as a result of engaging in truthful and non-misleading promotion of its drug, Vascepa.  He concluded:

“The Court’s considered and firm view is that, under Caronia, the FDA may not bring such an action based on truthful promotional speech alone, consistent with the First Amendment.  A fair reading of that decision refutes the FDA’s view that the Second Circuit’s ruling was limited to the facts of Caronia’s particular case.”

Instead, Judge Englemayer ruled that the Second Circuit’s Central Hudson analysis in Caronia made clear that restrictions on truthful, non-misleading speech aimed at preventing the misbranding of drugs must pass Constitutional muster, including being narrowly tailored.  He “reject[ed] the FDA’s reading of Caronia as a mere artifact of that case’s particular facts and circumstances.”

In analyzing the constitutionality of the FDA’s restriction on off-label promotion under the Central Hudson test, the Second Circuit outlined a pathway to off-label promotion that involved disclosures as a more narrowly tailored restriction on protected speech.  Judge Englemayer’s opinion in Amarin Pharma embraced this pathway.  He engaged in a thorough and thoughtful analysis of Amarin’s proposed disclosures and the FDA’s responses to those proposals to arrive at a set of disclosures intended to provide appropriate context to Amarin’s off-label messaging.

Time will tell whether the FDA also embraces this pathway.  The FDA has yet to hold the public meeting that it announced earlier this year would take place to gather information to allow the agency to further consider its position on off-label promotion.  It is unknown what impact Judge Englemayer’s decision in Amarin Pharma may have on that meeting.  It also is unknown what the FDA’s legal response will be to the decision.  Will the FDA let the decision lie and try to distinguish it on it facts, which may be easier to do than with Caronia?  Or will the agency accept the broader implications of the decision?

The broader implications of more truthful speech are better informed treatment decisions.  In weighing the balance of equities and the public interest as part of his analysis of the propriety of preliminary relief, Judge Englemayer came down firmly on the side of not chilling Amarin’s First Amendment rights and – following the precedent set in Caronia – against a regulatory scheme that seeks to criminalize speech, even truthful speech.

In this section of the Amarin Pharma opinion, Judge Englemayer dismissed the FDA’s argument that a ruling in favor of Amarin would undermine the drug approval process.  He chided the agency on this point when he stated:

“Had the FDA believed that Caronia gravely undermined the drug approval process, it should have sought review of that decision.”

As in Caronia, the FDA clearly did not get what it wanted in Amarin Pharma.  At some point, however, the agency just might find it got what it needs – a pathway that allows for truthful and non-misleading off-label promotion and provides health care professionals and the patients they treat with more information, not less.


Previous Post

Ethics and Compliance Programs in a Global and Brazilian Context: The 6 Principles of Compliance

Next Post

Classifying Employees as Exempt from Overtime May Become a Lot More Costly

Brian A. Dahl

Brian A. Dahl

Brian Dahl is the Principal at Dahl Compliance Consulting LLC. His consulting practice focuses on assisting life sciences companies with their corporate compliance needs. He is the architect of the corporate compliance programs at two top-tier pharmaceutical companies – Teva Pharmaceuticals and Takeda Pharmaceuticals.  As a consultant, he has built the compliance programs at two startup companies that recently launched their first products. Brian brings that real-world experience to the service of clients who are developing, implementing, or evaluating the effectiveness of their corporate compliance programs. Brian spent six years as the Compliance Director at Teva, where he built the company’s compliance program from the ground up while leading all aspects of the company’s compliance efforts across multiple branded divisions. Brian’s career in pharmaceutical corporate compliance began at Takeda in 2001, six months before the government’s seminal settlement with TAP Pharmaceuticals. Prior to becoming a pharmaceutical compliance professional, Brian practiced health law at the law firm of Baker & Daniels. He began his legal career practicing advertising law in Washington, D.C., first at the Federal Trade Commission and later at the law firm of Collier, Shannon, Rill & Scott. Brian received his J.D. from the University of Iowa College of Law and his Master of Health Administration degree from the College of Public Health at the University of Iowa. You can reach Brian at 847-800-1753 or at DahlComplianceConsulting@gmail.com.

Related Posts

Au10Tix AML Update

AU10TIX Adds Continuous Risk Monitoring to AML Platform

by Corporate Compliance Insights
May 15, 2025

Identity verification company AU10TIX has launched a continuous risk monitoring capability as part of its anti-money laundering solution, designed to...

MirrorWeb AI Launch

MirrorWeb Launches New AI-Powered Tool

by Corporate Compliance Insights
May 15, 2025

Communications supervision platform provider MirrorWeb has released Sentinel, a compliance solution powered in part by AI technology like natural language...

KovrAI Funding

Compliance Automation Startup Kovr.ai Emerges From Stealth With $3.6M Funding

by Corporate Compliance Insights
May 15, 2025

Cyber compliance automation firm Kovr.ai has emerged from stealth mode with $3.6 million in seed funding led by IronGate and...

Trustrace AI Update

TrusTrace Upgrades Supply Chain Data Platform With AI Capabilities

by Corporate Compliance Insights
May 15, 2025

Supply chain software company TrusTrace has launched an AI-driven upgrade to its data management platform, designed to help brands and...

Next Post
Classifying Employees as Exempt from Overtime May Become a Lot More Costly

Classifying Employees as Exempt from Overtime May Become a Lot More Costly

No Result
View All Result

Privacy Policy | AI Policy

Founded in 2010, CCI is the web’s premier global independent news source for compliance, ethics, risk and information security. 

Got a news tip? Get in touch. Want a weekly round-up in your inbox? Sign up for free. No subscription fees, no paywalls. 

Follow Us

Browse Topics:

  • CCI Press
  • Compliance
  • Compliance Podcasts
  • Cybersecurity
  • Data Privacy
  • eBooks Published by CCI
  • Ethics
  • FCPA
  • Featured
  • Financial Services
  • Fraud
  • Governance
  • GRC Vendor News
  • HR Compliance
  • Internal Audit
  • Leadership and Career
  • On Demand Webinars
  • Opinion
  • Research
  • Resource Library
  • Risk
  • Uncategorized
  • Videos
  • Webinars
  • Well-Being
  • Whitepapers

© 2025 Corporate Compliance Insights

Welcome to CCI. This site uses cookies. Please click OK to accept. Privacy Policy
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT
No Result
View All Result
  • Home
  • About
    • About CCI
    • CCI Magazine
    • Writing for CCI
    • Career Connection
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Library
    • Download Whitepapers & Reports
    • Download eBooks
    • New: Living Your Best Compliance Life by Mary Shirley
    • New: Ethics and Compliance for Humans by Adam Balfour
    • 2021: Raise Your Game, Not Your Voice by Lentini-Walker & Tschida
    • CCI Press & Compliance Bookshelf
  • Podcasts
    • Great Women in Compliance
    • Unless: The Podcast (Hemma Lomax)
  • Research
  • Webinars
  • Events
  • Subscribe

© 2025 Corporate Compliance Insights